Who Generates Higher Gross Profit? Novartis AG or Arrowhead Pharmaceuticals, Inc.

A Tale of Two Companies: Novartis AG vs. Arrowhead Pharmaceuticals, Inc.

In the competitive landscape of the pharmaceutical industry, gross profit is a key indicator of a company's financial health and market position. Over the past decade, Novartis AG has consistently outperformed Arrowhead Pharmaceuticals, Inc. in terms of gross profit. From 2014 to 2023, Novartis AG's gross profit has remained robust, averaging around $34.5 billion annually, with a peak of approximately $37 billion in 2021. In contrast, Arrowhead Pharmaceuticals, Inc. has shown significant growth, albeit on a smaller scale, with gross profits increasing from a modest $175,000 in 2014 to over $240 million in 2023. This represents a staggering growth rate of over 137,000% for Arrowhead. Despite this impressive growth, Novartis AG's financial prowess remains unmatched, highlighting the scale and reach of this pharmaceutical giant. Missing data for 2024 suggests a need for further updates to maintain accurate insights.